Physician profile
Maximo Navarro
NPI 1548261001
$5,810.30
in general payments reported to CMS, 2019-2025
23 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $911 · 2022: $2,037 · 2023: $815 · 2024: $1,308 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,693.43 | 2021-2025 | Mycarelink, Micra, Linq II |
| Boston Scientific Corporation | $788.33 | 2021-2025 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $514.93 | 2021-2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $414.53 | 2021-2025 | Lokelma, Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $197.70 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $170.63 | 2021-2024 | Xarelto |
| Cagent Vascular INC | $149.03 | 2025 | Serrantor |
| Abbott Laboratories | $136.08 | 2021-2023 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.51 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $98.91 | 2024 | Camzyos |
| Pfizer INC. | $76.91 | 2024-2025 | |
| Bridgebio Pharma, INC. | $63.76 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $54.17 | 2021-2025 | |
| Novo Nordisk INC | $53.38 | 2021-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $51.36 | 2021-2023 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.22 | 2024-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $48.54 | 2023 | Inpefa |
| Astellas Pharma US INC | $34.78 | 2021-2022 | |
| Atricure, INC. | $32.85 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.53 | 2022 | |
| Acutus Medical, INC. | $17.38 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.87 | 2025 | Evkeeza |
| Lilly USA, LLC | $16.47 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximo Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.